1,189 research outputs found
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546]
No full textThe name of the author Daniele Santini was inadvertently omitted from the author line. The correct author line is above
The Italiancross-sectionalsurvey of the management of bone metastasis: ZeTa study
No full textBackground
Several studies have emphasized the importance of the maintenance of bone health in a comprehensive cancer care. However, no survey about approach to bone metastasis care is currently available. The ZeTa study provides a picture of the Italian oncologists' therapeutics habits in this area, in a real clinical-practice scenario.
Design
This study was based on online questionnaire-based interviews to Italian oncologists that included 145 questions. The aim was to collect information on the treatment of bone metastasis, the current use of bisphosphonates, the awareness of guidelines and the concerns about ONJ, the use of vitamin D supplementation.
Results
445 oncologists were contacted, 283 agreed to participate. The results show that the current management of bone metastasis is still sub-optimal, as the recommendations from current clinical guidelines are not completely followed by all specialists.
Conclusions
This survey highlights the urgent need to improve management of bone metastasis in cancer patient
Bladder Cancer. Andrea Tubaro, Daniele Santini, Cosimo De Nunzio, Alice Zoccoli, Michele Iuliano. In Biotargets of cancer in current clinical practice. M Bologna Editors. Springer edition. 2012
No full textVariazione della corrente di tunnel come conseguenza della concentrazione di cariche "intrappolate"
No full text
Dizionario del dialetto veneziano /
No full text"Edito per cura di Daniele Manin.""Errata corrige": p. 801-802."Indice degli autori e de' libri consultati per l'opera presente": page xi
Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates
No full textFor patients with malignant bone disease, bisphosphonate therapy is the standard treatment. Preclinical and preliminary clinical data suggest that bisphosphonates have direct or indirect antitumor effects: they affect growth-factor release, cancer-cell adhesion, invasion and viability, angiogenesis, and apoptosis of cancer cells. These effects might be enhanced through coadministration with chemotherapy agents, biological agents, or both. We survey the biochemical pathways and molecular targets of bisphosphonates, and discuss the molecular mechanisms of these antitumor effects, as well as the documented antineoplastic preclinical effects of bisphosphonates used in combination with cytotoxic and biological drugs. Moreover, the positive interactions between bisphosphonates and farnesyltransferase inhibitors, KIT receptor tyrosine kinase inhibitors ( e. g. imatinib mesylate) and cyclooxygenase-2 inhibitors are discussed in relation to their potential synergistic and additive effects. We briefly discuss identification of new molecular targets of bisphosphonates from genomic and proteomic analysis, and highlight the cellular consequences of drug-related enzyme inhibition
Towards a similarity-based web service discovery through soft constraint satisfaction problems
No full textIn this paper, we focus on the discovery process of Web Services (WSs) by basing the search on the similarities among the service requirements and candidate search results, in order to cope with over-constrained queries or to find satisfactory alternatives for user requirements. This discovery process needs to involve the so-called Soft Constraint Satisfaction Problems (SCSPs). First we represent both WSs and the search query of the user as Rooted Trees, i.e., a particular form of Conceptual Graphs. Then, we find a homomorphism between these two trees as a solution of an SCSP. The main contribution of this paper is the enhanced expressiveness offered by this "softness": in over-constrained scenarios, when a user query cannot be satisfied, classical crisp constraints (i.e., CSP) are not expressive enough to find "close" solutions to meet the users' needs
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid
No full textDenosumab (Dmab) and zoledronic acid (ZOL) are antiresorptive agents, with different mechanisms of action, that are indicated for delaying the onset of skeletal-related events in patients with bone metastases from solid tumors. Clinical and preclinical data suggest that ZOL may have also anti-angiogenic activity; however, the effects of Dmab (a fully humanized antibody against the receptor activator of nuclear factor kappa B ligand) on angiogenesis are largely unknown. The objective of this study was to compare the potential anti-angiogenic activity of Dmab with that of ZOL in preclinical models. Dmab (0.31 to 160 mu M) had no effect on the viability of human MDA-MB-436 and CG5 breast cancer cells or human umbilical vein endothelial cells (HUVECs) and no effect on tubule formation or invasion of HUVECs. In contrast, ZOL (0.31 to 160 mu M) decreased the viability of breast cancer and HUVECs in a time-and concentration-dependent manner and also inhibited HUVEC tubule formation and invasion. In vivo, ZOL (20 mu g/mouse three times a week for three consecutive weeks) inhibited angiogenesis in Matrigel plugs and inhibited the growth and neo-angiogenesis of CG5 xenografts in athymic nude mice. In contrast, Dmab (10 mg/kg twice a week for four consecutive weeks) had no effect on Matrigel vascularization or xenograft growth in this model. These findings support the potential antiangiogenic and anticancer activity of ZOL in vitro and in vivo and further suggest that Dmab does not have antiangiogenic activity. Additional studies are needed to elucidate the potential anticancer activity of Dmab
- …
